Novartis Launches MS Research Study Using Smartphones
Novartis announced the launch of a mobile research study called Evaluation of Evidence from Smart Phone Sensors and Patient-Reported Outcomes in Participants with Multiple Sclerosis (elevateMS)-a mobile research study for people with multiple sclerosis (MS)-that collects data through the participants’ smartphone, eliminating the need for clinic visits. The study is designed to gather sensor-based data from physical tasks and symptoms.
The study aims to expand understanding of the daily challenges patients with MS can have and to uncover new potential capacities of treatment effectiveness through real-time data collection from participants in their everyday life. Researchers will use the participants’ data to understand what it is like to live with MS.
The elevateMS study was developed in partnership with Sage Bionetworks and uses a mobile application that was built on the Apple ResearchKit platform. The platform allows participants to contribute from home or on the go, and allow researchers to collect data in the participant’s everyday life. The mobile app was designed with input from patients, neurologists, and advocates. To download the app and enroll in the study, click here.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
